ARIAD Announces Recommendation Of Following Second Interim Analysis Of Phase 3 Succeed Trial Of Oral Ridaforolimus, an Investiga

ARIAD Pharmaceuticals, Inc. announced that the independent Data Monitoring Committee (DMC) of the Phase 3 SUCCEED trial has completed the second interim efficacy analysis as specified in the study protocol and has recommended that the randomized, placebo-controlled trial of oral ridaforolimus in patients with metastatic sarcomas continue to its final analysis, without modification to the study protocol.